MA-WHOOP
WHOOP, the human performance company, today announced the expansion of its global footprint, now shipping to 56 markets worldwide, with more launches ahead. Additionally, the WHOOP app is now available in Italian and Spanish (Latin America), as well as English, French, and German. To support continued growth and momentum, WHOOP named new leaders to its C-suite to deliver on the WHOOP mission of helping people achieve their goals, by providing best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, strain, and health. To help everyone start their journey, WHOOP is currently offering a one-month free trial that can be accessed on WHOOP.com.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429085870/en/
WHOOP announces significant global expansion, appoints new senior leadership. Continues "Free Trials," making it the only wearable to offer "Try Before You Buy." (Photo: Business Wire)
WHOOP Global Expansion
With a commitment to serving its global community to unlock their potential, WHOOP has expanded its reach to several key markets and regions, where there’s been rising consumer demand for and adoption of the brand. Consumers in Qatar, Saudi Arabia, Kuwait, Bahrain, Hong Kong, Israel, Korea, and Taiwan can now purchase WHOOP directly and the brand will ship to each of these markets, creating a seamless experience for its members.
The Gulf is a key region for the brand’s growth. In fact, their digital health market is expected to witness healthy, double-digit growth by 2027, according to Medi-Tech Insights. As a world class health and performance monitor, WHOOP provides coaching to improve overall well-being and foster behavior change.
To support global expansion, the WHOOP app is now available in Italian and Latin American Spanish to complement its existing languages: English, French and German, with additional language rollouts to come. This expansion ensures that WHOOP members worldwide can access the full suite of content and features in their native language.
“WHOOP is experiencing remarkable growth and momentum, particularly in new markets around the world. We’re excited to open these new markets and provide over 125 million people with access to WHOOP,” said Will Ahmed, Founder and CEO of WHOOP. “This market growth and the launch of Spanish and Italian in the WHOOP app is just the start of our international expansion. Our teams, including those led by three of our newest C-suite leaders, are working every day to unlock new markets and help introduce new members to the power of our WHOOP membership.”
New Executive Leadership at WHOOP
To spearhead continued growth and global expansion, WHOOP has appointed new leaders to its executive team:
- Ed Baker joins WHOOP as Chief Growth Officer, following the acquisition of Baker's previous company, AnyQuestion. Before that, Baker led growth teams at Facebook and Uber during periods of extraordinary growth. He has also served on the WHOOP Board of Directors for nearly five years. Baker will lead efforts to fuel the next phase of hyper-growth at WHOOP.
- Michener Chandlee is now Chief Financial Officer at WHOOP, leveraging his extensive financial expertise to drive strategic financial planning and operational excellence. Prior to WHOOP, Chandlee was the CFO of Fanatics and also spent nearly 20 years at Nike in various leadership roles, including Chief Risk Officer and CFO of Nike’s Global Marketplace.
- John Sullivan has been promoted to Chief Marketing Officer, bringing his wealth of experience in marketing strategy and brand development to further elevate the presence of WHOOP in the global marketplace. Sullivan has worked at WHOOP for more than seven years during which he’s developed the direct-to-consumer business at WHOOP, overseeing all marketing functions of Brand, Commercial, Lifecycle, Business Development and Accessories and Apparel. Prior to WHOOP, he held positions in marketing at Tracksmith, Puma and Monitor Group, a strategy consulting firm.
To learn more and discover how WHOOP helps its members unlock their performance, go to www.whoop.com. To make it even more convenient than ever before to access WHOOP, it is available for purchase on Amazon.com, as well as at Best Buy and Dick’s Sporting Goods.
ABOUT WHOOP
WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. WHOOP Unite is a comprehensive solution dedicated to supporting organizations across a wide range of industries with coaching, organizational insights, and health programs. Studies show WHOOP can positively change behavior, increase sleep, and improve physiological biomarkers. Founded in 2012, WHOOP is based in Boston and has raised more than $400 million in venture capital. The latest round of financing made WHOOP the world's most valuable standalone wearables company. Visit WHOOP.com for more information and connect with WHOOP on Instagram, Twitter, Facebook, LinkedIn, and YouTube.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240429085870/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
